JHL Biosimilar Pipeline

JHL1101, our lead therapeutic, is a proposed biosimilar of rituximab. JHL1101 is currently undergoing clinical trials in the European Union, and an application to conduct clinical trials in China has been filed with the CFDA and is under review. JHL is also developing JHL1922, a proposed biosimilar of dornase alfa, JHL1149, a proposed bevacizumab biosimilar, and JHL1188, a proposed biosimilar of trastuzumab.

Potential Indication / Disease Area
JHL1101 (Biosimilar Rituximab) Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Follicular lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiites, and microscopic polyangiites Anti-CD20 monoclonal antibody
EU Phase I
China Phase I + III approval stage
JHL1922  (Biosimilar Dornase Alfa) Orphan Drug – Cystic Fibrosis Enzyme biologic
Global Phase I in progress
JHL1149  (Biosimilar Bevacizumab) Metastatic colorectal cancer, Advanced nonsquamous non-small cell lung cancer, Platinum-resistant ovarian cancer, Advanced cervical cancer, Metastatic renal cell carcinoma and Recurrent glioblastoma. Anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody
EU Phase I accepted
China Phase I + III submission accepted
JHL1188  (Biosimilar Trastuzumab) HER 2+ breast cancer
HER 2+ gastric cancer
Anti-HER2 monoclonal antibody
EU/China Phase I filing in progress
China Pre-Clinical Studies in progress
JHL1211 (Biosimilar Omalizumab) Allergic Asthma, Chronic Idiopathic Urticaria A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE)
Pre-Clinical Stage
JHL1199 (Biosimilar Pertuzumab) Inflammatory carcinoma of the breast, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer (MBC), Stage I Breast Carcinoma A recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of HER2.
Pre-Clinical Stage
JHL1266 (Biosimilar Denosumab) Osteoporosis, Bone CancerBone Loss, Bone pain, Fracture Bone, Spinal Cord Compression, Bone destruction, Giant cell tumor of the bone, High risk of fracture, Refractory Hypercalcemia of malignancy A novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL)
Pre-Clinical Stage

Interested in working with us?

JHL is open for partnerships and license agreements for its biosimilar assets worldwide. We can offer you access to our expertise in process development, manufacturing and regulatory management.